Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Vesting of Options under Long-Term Incentive Plan

30 June 2026: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces the outcome of performance conditions and the resulting vesting of options under the terms of the Company's Long-Term Incentive Plan ("LTIP") adopted on 26 June 2024 and announced to the market on 4 July 2024.

The LTIP issued share options to key members of Allergy Therapeutics' management team including certain of its persons discharging managerial responsibilities ("PDMRs"), to encourage long-term value creation and to incentivise those individuals in a manner that aligns with the interests of the Company's stakeholders. The Remuneration Committee set performance conditions across a three-year performance period commencing 1 July 2023 to 30 June 2026, comprising: (i) a share price threshold applicable to the whole award; (ii) EBITDA performance targets (representing 70 per cent. of each award); and (iii) regulatory performance targets (representing 30 per cent. of each award).

Performance Outcome

The Remuneration Committee has reviewed and assessed performance against the conditions attached to the LTIP awards over the performance period. The share price threshold having been met, the regulatory performance targets (representing 30 per cent. of each award) have been achieved and accordingly 30 per cent. of each award has vested. The EBITDA performance targets (representing 70 per cent. of each award) have not been achieved and accordingly 70 per cent. of each award has lapsed.

Under this award, a total of 7,671,078 share options have vested with an exercise price of £0.001 per share, and a total of 17,899,201 share options have lapsed. The table below sets out the vesting positions of Manuel Llobet and Shaun Furlong, being the PDMRs of the Company who participated in the award:

The exercise price of the vested options is £0.001 per Ordinary Share. Following vesting, the options are exercisable by the relevant PDMR and, upon exercise, new Ordinary Shares will be issued or existing Ordinary Shares transferred to the relevant PDMR in accordance with the terms of the LTIP. The Company will make a further announcement in the event that any such options are exercised.

- ENDS -

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash / Giles Balleny / Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

ICR Healthcare

Mary-Jane Elliott / David Daley

+44 (0)20 3709 5700

[email protected]

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focused on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the UK Market Abuse Regulation